Regenxbio Inc (NASDAQ: RGNX) kicked off on Monday, up 5.58% from the previous trading day, before settling in for the closing price of $8.24. Over the past 52 weeks, RGNX has traded in a range of $5.62-$22.84.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 87.87% over the past five years. While this was happening, its average annual earnings per share was recorded 89.41%. With a float of $45.20 million, this company’s outstanding shares have now reached $49.55 million.
Let’s look at the performance matrix of the company that is accounted for 353 employees. In terms of profitability, gross margin is 49.84%, operating margin of -277.51%, and the pretax margin is -272.54%.
Regenxbio Inc (RGNX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Regenxbio Inc is 9.75%, while institutional ownership is 86.27%. The most recent insider transaction that took place on Dec 30 ’24, was worth 148,504. Before that another transaction happened on Oct 01 ’24, when Company’s Director sold 10,000 for $10.11, making the entire transaction worth $101,052. This insider now owns 11,286 shares in total.
Regenxbio Inc (RGNX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 89.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.63% during the next five years compared to -12.18% drop over the previous five years of trading.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Take a look at Regenxbio Inc’s (RGNX) current performance indicators. Last quarter, stock had a quick ratio of 2.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.64, a number that is poised to hit 0.48 in the next quarter and is forecasted to reach -1.07 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Regenxbio Inc (NASDAQ: RGNX) saw its 5-day average volume 1.58 million, a positive change from its year-to-date volume of 1.0 million. As of the previous 9 days, the stock’s Stochastic %D was 81.20%. Additionally, its Average True Range was 0.61.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 46.67%, which indicates a significant decrease from 89.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.94% in the past 14 days, which was lower than the 77.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.33, while its 200-day Moving Average is $10.02. Nevertheless, the first resistance level for the watch stands at $8.93 in the near term. At $9.15, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.49. If the price goes on to break the first support level at $8.37, it is likely to go to the next support level at $8.03. The third support level lies at $7.81 if the price breaches the second support level.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
The company with the Market Capitalisation of 435.75 million has total of 50,086K Shares Outstanding. Its annual sales at the moment are 83,330 K in contrast with the sum of -227,100 K annual income. Company’s last quarter sales were recorded 21,210 K and last quarter income was -51,190 K.
